GlassScriptPhysician profile
Philippe Martineau
NPI 1073516522
$6,331.18
in general payments reported to CMS, 2019-2025
21 companies · $1,453 in 2025
The $1,453 reported for 2025 was more than what 86% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,189 · 2020: $304 · 2022: $24.63 · 2023: $1,006 · 2024: $2,355 · 2025: $1,453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,493 · Education: $320.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,493.45 |
| Education | $319.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,811.35 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,312.12 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Corium, LLC | $731.35 | 2023-2025 | Azstarys |
| Lundbeck LLC | $575.82 | 2019-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $437.74 | 2020-2025 | Trintellix |
| Sunovion Pharmaceuticals INC. | $215.27 | 2019 | |
| Neurocrine Biosciences, INC. | $190.51 | 2020-2025 | Ingrezza |
| Almatica Pharma LLC | $164.10 | 2023-2024 | Loreev Xr |
| Janssen Pharmaceuticals, INC | $162.92 | 2019 | |
| Alkermes, INC. | $146.64 | 2024-2025 | Aristada, Lybalvi |
| Shire North American Group INC | $113.74 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $99.48 | 2024-2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $86.42 | 2023-2025 | Caplyta |
| Allergan, INC. | $55.41 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $51.31 | 2019-2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $42.80 | 2024-2025 | Auvelity |
| Orexo US, INC. | $40.15 | 2023-2024 | Zubsolv |
| Neos Therapeutics, LP | $36.33 | 2024-2025 | Adzenys Xr-Odt |
| Neuronetics, INC. | $25.99 | 2019 | |
| Idorsia Pharmaceuticals US INC | $19.07 | 2024 | Quviviq |
| Ironshore Pharmaceuticals INC. | $12.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philippe Martineau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.